FDA Addresses Manufacturing Disruptions

The FDA is working with manufacturers to notify stakeholders of the potential discontinuation or interruption of drug and biological product manufacturing that arise due to the disruption caused by COVID-19. 

If drug shortages arise, the FDA hopes to have advance notice to mitigate the impact, and will work to communicate potential shortages. Healthesystems continues to monitor published drug shortage information and identify any supply issues that may impact our injured workers.